Nanobiotix S.A. American Depositary Shares

NBTXNASDAQ

Market cap

$2.52B

Employees

97

Exchange

NASDAQ

About Nanobiotix S.A. American Depositary Shares

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Country

US

Website

www.nanobiotix.com

NBTX news

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

Nanobiotix announced the pricing of an oversubscribed €85 million global offering, indicating strong investor demand for the company's securities. The oversubscription suggests confidence in the biotech firm's financial prospects and strategic direction. The capital raise will likely support the company's research and development initiatives.

GlobeNewswire Inc. · May 21, 2026